Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Nov:137:113-122.
doi: 10.1016/j.lungcan.2019.09.017. Epub 2019 Sep 23.

Optimizing the sequencing of tyrosine kinase inhibitors (TKIs) in epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC)

Ana C Z Gelatti  1 , Alexander Drilon  2 , Fernando C Santini  3
Affiliations
Review

Optimizing the sequencing of tyrosine kinase inhibitors (TKIs) in epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC)

Ana C Z Gelatti et al. Lung Cancer. 2019 Nov.

Abstract

Non-small cell lung cancer (NSCLC) is the most common type of lung cancer, accounting for 80-85% of cases. Epidermal growth factor receptor (EGFR) mutations are observed in approximately 40% and 20% of patients with NSCLC in Asian and non-Asian populations, respectively. First-generation (gefitinib, erlotinib) and second-generation (afatinib, dacomitinib) EGFR-tyrosine kinase inhibitors (TKIs) have been standard-of-care (SoC) first-line treatment for patients with sensitizing EGFR mutation positive advanced NSCLC following Phase III trials versus platinum-based doublet chemotherapy. However, most patients treated with first-line first- or second-generation EGFR-TKIs develop resistance. Osimertinib, a third-generation, central nervous system active EGFR-TKI which potently and selectively inhibits both EGFR-TKI sensitizing (EGFRm) and the most common EGFR T790 M resistance mutations, has shown superior efficacy versus first-generation EGFR-TKIs (gefitinib / erlotinib). Osimertinib is now a treatment option for patients with advanced NSCLC harboring EGFRm in the first-line setting, and treatment of choice for patients with T790 M positive NSCLC following disease progression on first-line EGFR-TKIs. The second-generation EGFR-TKI dacomitinib has also recently been approved for the first-line treatment of EGFRm positive metastatic NSCLC. There remains a need to determine appropriate sequencing of EGFR-TKIs in this setting, including EGFR-TKIs as monotherapy or in combination with other TKIs / signaling pathway inhibitors. This review considers the evolving role of sequencing treatments to maximize benefits for patients with EGFRm positive advanced NSCLC.

Keywords: Epidermal growth factor receptor; Exon 19 deletion; Exon 21 mutation; Non-small cell lung cancer; Sequencing; Tyrosine kinase inhibitor.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Median PFS with first-line EGFR-TKI treatment in EGFR mutation-positive NSCLC and the proportion of patients who received subsequent systemic treatment [6-12,19,29,32,33,102,103,138-142] *As a proportion of patients who discontinued EGFR-TKI at data cut-off; treatment presumed systemic when details not provided; however, some references are not clear in this respect. Note, due to the differences in trial designs and patient populations, cross-trial comparisons should be interpreted with caution.
Figure 2.
Figure 2.
Approximation of proportion of patients with EGFRm positive advanced NSCLC treated with first- / second-generation EGFR-TKIs and who go on to receive osimertinib as second-line therapy [6-12,19,93,95,98,102,103,111,138-140,143-145] *Based on the proportion of patients who discontinued first-line EGFR-TKIs in randomized-controlled trials and who received subsequent systemic treatment: 47–82% †Based on real-world evidence studies indicating the proportion of patients who received an EGFR T790M test: FLATIRON (30%) and REMEDY (97% of patients with samples collected) ¶Based on a meta-analysis of literature indicating a prevalence of 50% (Wang et al. BMC 2018), and real-world evidence studies indicating a lower than expected T790M positive rate: FLATIRON (28%) and REMEDY (31%) §Based on real-world evidence studies, the vast majority of patients who test positive for T790M receive osimertinib treatment: FLATIRON (96%) and REMEDY (90%) FLATIRON: US Flatiron Electronic Health Record-derived database study REMEDY: A prospective study of molecular testing status in the EGFR mutation positive NSCLC patients with disease progression during EGFR-TKI treatment
Figure 3
Figure 3
A. Resistance mechanisms post ≥second-line osimertinib* [146-152] Composite pie chart (range of data values correspond to the size of each segment) *Resistance mechanism reported may overlap with another †Resistance mechanisms in plasma; frequency of MET amplification is expected to be higher in tissue B. Plasma-based resistance mechanisms post first-line osimertinib (FLAURA)* [112] *Resistance mechanism reported may overlap with another †Resistance mechanisms in plasma; frequency of MET amplification is expected to be higher in tissue
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. World Health Organization. Cancer - Key facts, 2018. Available at http://www.who.int/news-room/fact-sheets/detail/cancer accessed on 20 February.
    1. Planchard D, Popat S, Kerr K, Novello S, Smit EF, Faivre-Finn C, et al. Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2018;29:iv192–iv237. - PubMed
    1. Kalemkerian GP, Narula N, Kennedy EB, Biermann WA, Donington J, Leighl NB, et al. Molecular Testing Guideline for the Selection of Patients With Lung Cancer for Treatment With Targeted Tyrosine Kinase Inhibitors: American Society of Clinical Oncology Endorsement of the College of American Pathologists/International Association for the Study of Lung Cancer/Association for Molecular Pathology Clinical Practice Guideline Update. J Clin Oncol 2018;36:911–9. - PubMed
    1. Zhang YL, Yuan JQ, Wang KF, Fu XH, Han XR, Threapleton D, et al. The prevalence of EGFR mutation in patients with non-small cell lung cancer: a systematic review and meta-analysis. Oncotarget 2016;7:78985–93. - PMC - PubMed
    1. Cho J, Chen L, Sangji N, Okabe T, Yonesaka K, Francis JM, et al. Cetuximab response of lung cancer-derived EGF receptor mutants is associated with asymmetric dimerization. Cancer Res 2013;73:6770–9. - PMC - PubMed

Publication types

MeSH terms